{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:39:20Z","timestamp":1793612360679,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00082","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:06:03Z","timestamp":1590138363000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":243,"title":["New Therapies for Advanced Thyroid Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Diprajan","family":"Laha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriem","family":"Boufraqech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1089\/thy.2007.0061","article-title":"Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications","volume":"17","author":"Ghossein","year":"2007","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/hed.21494","article-title":"Aggressive variants of papillary thyroid carcinoma","volume":"33","author":"Silver","year":"2011","journal-title":"Head Neck"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2016-203930","article-title":"Non-invasive follicular thyroid neoplasm with papillary-like nuclei: reducing overtreatment by reclassifying an indolent variant of papillary thyroid cancer","volume-title":"J Clin Pathol","author":"Poller","year":"2016"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/00000478-200112000-00002","article-title":"Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior","volume":"25","author":"Nikiforov","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2010-0405","article-title":"Follicular adenoma and carcinoma of the thyroid gland","volume":"16","author":"McHenry","year":"2011","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1210\/jc.2004-2281","article-title":"Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors","volume":"90","author":"Wu","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/cncr.23869","article-title":"Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase\/AKT signaling pathway in thyroid tumors","volume":"113","author":"Hou","year":"2008","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cncr.20087","article-title":"Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients","volume":"100","author":"Volante","year":"2004","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/cncr.21739","article-title":"Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients","volume":"106","author":"Hiltzik","year":"2006","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1210\/jc.2013-2503","article-title":"The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations","volume":"99","author":"Jung","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1172\/JCI116385","article-title":"Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland","volume":"91","author":"Donghi","year":"1993","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0002-9440(10)64045-X","article-title":"Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis","volume":"158","author":"Garcia-Rostan","year":"2001","journal-title":"Am J Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","article-title":"Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany","volume":"175","author":"Wendler","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0025-6196(12)65285-9","article-title":"Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases","volume":"60","author":"Nel","year":"1985","journal-title":"Mayo Clin Proc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E1292","DOI":"10.3390\/ijms18061292","article-title":"Differentiated thyroid cancer-treatment: state of the art","volume":"18","author":"Schmidbauer","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00001622-200101000-00008","article-title":"Recombinant human thyrotropin in the management of thyroid cancer","volume":"13","author":"McDougall","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"B25","first-page":"30","article-title":"Thyroid gland malfunction","volume-title":"MMW Fortschr Med","author":"Brabant","year":"2004"},{"key":"B26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1089\/thy.1998.8.737","article-title":"Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry","volume":"8","author":"Cooper","year":"1998","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/thy.2009.0311","article-title":"Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer","volume":"20","author":"Biondi","year":"2010","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cncr.30360","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?","volume":"123","author":"Haugen","year":"2017","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0304-419X(03)00016-7","article-title":"Raf proteins and cancer: B-Raf is identified as a mutational target","volume":"1653","author":"Mercer","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/jc.2009-0373","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells","volume":"95","author":"Salerno","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1210\/jc.2007-1184","volume":"92","author":"Ball","year":"2007","journal-title":"Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1\/2 inhibitor AZD(6244)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1210\/jc.2007-2825","article-title":"BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines","volume":"93","author":"Leboeuf","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/1878-0261.12070","article-title":"Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines","volume":"11","author":"Vitale","year":"2017","journal-title":"Mol Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"39702","DOI":"10.18632\/oncotarget.4052","article-title":"mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib","volume":"6","author":"Hanly","year":"2015","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"18038","DOI":"10.18632\/oncotarget.3833","article-title":"Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis","volume":"6","author":"Sadowski","year":"2015","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell."},{"key":"B37","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","article-title":"Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer","volume":"7","author":"Brauner","year":"2016","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/ijc.32041","article-title":"Anti-PD-1\/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"Gunda","year":"2019","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","article-title":"Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer","volume":"64","author":"Cantara","year":"2019","journal-title":"Endocrine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1074\/mcp.M116.058925","article-title":"Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer","volume":"15","author":"Hutton","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3410\/f.717987086.793472329","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","article-title":"BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PT","volume":"22","author":"Soares","year":"2003","journal-title":"Oncogene C"},{"key":"B44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fendo.2015.00176","article-title":"Molecular targeted therapies of aggressive thyroid cancer","volume":"6","author":"Ferrari","year":"2015","journal-title":"Front Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17446651.2017.1340155","article-title":"Novel treatment options for anaplastic thyroid cancer","volume":"12","author":"Fallahi","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-1881","article-title":"A Phase I Trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers","volume-title":"Clin Cancer Res","author":"Kurzrock","year":"2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jc.2017-00661","article-title":"Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial","volume":"102","author":"Schneider","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1530\/eje.1.02009","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop","volume":"153","author":"Vieira","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1530\/EJE-10-0967","article-title":"VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma","volume":"164","author":"Karaca","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12885-019-5541-4","article-title":"Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial","volume":"19","author":"Brown","year":"2019","journal-title":"BMC Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"B64","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/ERC-17-0532","article-title":"Immune landscape of papillary thyroid cancer and immunotherapeutic implications","volume":"25","author":"Na","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0142656","DOI":"10.1371\/journal.pone.0142656","article-title":"High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS ONE"},{"key":"B67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ctrv.2014.12.013","article-title":"PD-1 blockade therapy in renal cell carcinoma: current studies and future promises","volume":"41","author":"Massari","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B68","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:06:06Z","timestamp":1590138366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":68,"alternative-id":["10.3389\/fendo.2020.00082"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00082","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"article-number":"82"}}